Top-News
Biotechnologie USA

Heron Therapeutics Inc. News

Aktie
WKN:  A1XB6K ISIN:  US4277461020 US-Symbol:  HRTX
3,1097 €
-0,0047 €
-0,15%
3,325 $ 26.06.24
Handeln Depot/Watchlist
Aktienanzahl *
150,07 Mio.
Marktkapitalisierung *
426,52 Mio. €
Streubesitz
18,83%
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 22.01.2024

Heron Therapeutics Inc. News

29.05.24 - PR Newswire
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire
07.05.24 - PR Newswire
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire
24.04.24 - PR Newswire
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 PR Newswire
11.04.24 - PR Newswire
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire
28.03.24 - PR Newswire
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire
12.03.24 - PR Newswire
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates PR Newswire
28.02.24 - PR Newswire
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 PR Newswire
23.01.24 - PR Newswire
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures PR Newswire
07.01.24 - PR Newswire
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-​Opioid Dual Acting Local Anesthetic ...
14.11.23 - PR Newswire
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance PR Newswire
07.11.23 - PR Newswire
Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 PR Newswire
14.08.23 - PR Newswire
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates PR Newswire
24.07.23 - PR Newswire
Heron Therapeutics Announces Cost Reduction Plan and Restructuring
Heron Therapeutics Announces Cost Reduction Plan and Restructuring PR Newswire
24.07.23 - PR Newswire
Heron Therapeutics Announces $30 Million Private Placement Financing
Heron Therapeutics Announces $30 Million Private Placement Financing PR Newswire
23.06.23 - PR Newswire
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer PR Newswire
12.06.23 - PR Newswire
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer PR Newswire
11.05.23 - PR Newswire
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates PR Newswire
04.05.23 - PR Newswire
Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 PR Newswire
20.04.23 - PR Newswire
Heron Therapeutics Announces Commercial Leadership Changes
Heron Therapeutics Announces Commercial Leadership Changes PR Newswire
17.04.23 - PR Newswire
Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference
Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
20.06.24
Technical Trading: Gold Long bis Juli 2025
Gold Long Typ: Unlimited Turbo WKN: JK19UQ Hebel: 8,57 Laufzeit: OpenEnd Einstieg: Market ... Mehr »